WALTHAM, Mass.--(BUSINESS WIRE)--
Inc. (the "Company") (Nasdaq: NURO), a medical device company
focused on the treatment and management of the neurological
complications of diabetes, today announced that Jiro Nakamura, M.D.,
Ph.D., has joined its Scientific Advisory Board. Dr. Nakamura is
Professor, Division of Diabetes, Department of Internal Medicine,
Diabetes Center at the Aichi Medical University School of Medicine in
Dr. Nakamura has focused on diabetes throughout his career. His
particular emphasis has been on the vascular and cardio-vascular
complications of diabetes as well as on diabetic neuropathy. Dr.
Nakamura has published widely, been the Principal Investigator on a
range of clinical studies, and serves on the editorial boards of the
Journal of Diabetes Investigation, Diabetology International, and
Experimental Diabetes Research. He is a Member of the American Diabetes
Association, International Diabetes Federation, Japan Diabetes Society
and other professional societies, often serving as a Board Member or
Member of the Scientific Committee. Dr. Nakamura is considered a leader
in the field of diabetes research and treatment.
"We are honored that Dr. Nakamura has joined our Scientific Advisory
Board," said Shai N. Gozani, M.D., Ph.D., President and Chief Executive
Officer of NeuroMetrix. "This eminent group of international leaders in
the detection, management and treatment of the neurological
complications of diabetes plays a key role in our product development
efforts. Dr. Nakamura's position in the Japan medical profession and
understanding of local medical practice will be a valuable near-term
source of advice and guidance as we move toward the launch of NC-stat
DPNCheck in the Japanese market during 2014."
Dr. Nakamura will join the following members of the NeuroMetrix
David. G. Armstrong, D.P.M., M.D., Ph.D. - Professor of Surgery at the
University of Arizona and co-founder of the Southern Arizona Limb
Salvage Alliance (SALSA).
Andrew J.M. Boulton, M.R.C.P.(UK), M.D., F.R.C.P - Professor of Medicine
at the University of Manchester and Consulting Physician, Manchester
Royal Infirmary, Manchester, U.K. and Professor of Medicine, Diabetes
Research Institute, University of Miami.
Bruce A. Perkins, M.D., M.P.H., F.R.C.P. (C) - Assistant Professor at
the University of Toronto, Canada.
Soloman Tesfaye, M.B., Ch.B., M.D., F.R.C.P., (UK) - Consultant
Physician/Endocrinologist at the Royal Hallamshire Hospital, Sheffield,
U.K. and Honorary Professor of Diabetic Medicine at the University of
Aaron I. Vinik, M.D., Ph.D., F.C.P., F.A.C.P. (FRCP) - Professor of
Medicine, Pathology and Neurobiology and Director of Research at the
Neuroendocrine Unit of the Strelitz Diabetes Center for Endocrine and
Metabolic Disorders, Eastern Virginia Medical School, Norfolk, Virginia.
Dan Ziegler, M.D., F.R.C.P.E - Professor of Medicine at the Institute
for Clinical Diabetology, German Diabetes Center at the Heinrich Heine
University, and the Department of Metabolic Diseases, University
Hospital, Dusseldorf, Germany.
NeuroMetrix is a medical device company that develops and markets home
use and point-of-care devices for the treatment and management of
chronic pain, peripheral neuropathies, and associated neurological
disorders. The Company is presently focused on diabetic neuropathies,
which affect over 50% of people with diabetes. If left untreated,
diabetic neuropathies trigger foot ulcers that may require amputation
and cause disabling chronic pain. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company markets the SENSUS™ Pain Management System for treating chronic
pain, focusing on physicians managing patients with painful diabetic
neuropathy. The company also markets the DPNCheck® device,
which is a rapid, accurate, and quantitative point-of-care test for
diabetic neuropathy. This product is used to detect diabetic neuropathy
at an early stage and to guide treatment. For more information, please
Thomas T. Higgins, 781-314-2761
Chief Financial Officer
Source: NeuroMetrix, Inc.
News Provided by Acquire Media